stockrow
Friday 6 November 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
49.92
1.36
+2.80%
Follow CRSP
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
212.61 | 393.06 | 1,113.61 | 1,343.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(59.67) | (63.04) | (41.96) | (50.95) | |
P/B ratio |
3.25 | 3.01 | 2.52 | 2.45 | |
Price to Tangible BV |
3.25 | 3.01 | 2.52 | 2.45 | |
EV/Sales |
145.64 | 260.28 | 661.18 | 845.25 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.79) | (9.43) | (6.78) | (8.60) | |
EV/FCF |
(9.73) | (9.39) | (6.76) | (8.58) | |
Quick Ratio |
16.12 | 17.79 | 17.92 | 13.25 | |
Current Ratio |
16.21 | 17.85 | 17.96 | 13.32 | |
Net Debt/EBITDA |
13.40 | 15.74 | 14.74 | 13.25 | |
Debt/Assets |
22.96% | 22.11% | 21.48% | 0.00% | |
Debt/Equity |
0.36 | 0.34 | 0.32 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.92 | 0.89 | 0.71 | |
Capex/Depreciation |
(0.10) | (0.15) | (0.12) | (0.09) | |
Research and Development Expense of Revenue |
659.59% | 683.87% | 4,703.29% | 9,667.36% | |
Selling, General and Administrative Expense of Revenue |
141.03% | 172.41% | 1,178.53% | 2,129.51% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
141.77% | 170.08% | 1,119.62% | 2,092.13% | |
Graham Net Nets |
0.26 | 0.28 | 0.34 | 0.35 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.57%) | (8.73%) | (13.08%) | (12.43%) | |
Free Cash Flow Yield |
(7.04%) | (7.05%) | (8.78%) | (7.34%) | |
Revenue per Share |
0.13 | 0.11 | 0.02 | 0.01 | |
Operating CF per Share |
(0.93) | (0.87) | (1.13) | (1.03) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.93) | (0.87) | (1.14) | (1.03) | |
Cash per Share |
23.49 | 24.50 | 25.42 | 21.97 | |
Shareholders Equity per Share |
17.04 | 18.10 | 18.89 | 21.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.04 | 18.10 | 18.89 | 21.37 | |
Free Cash Flow |
(90.10) | (84.15) | (109.40) | (93.07) | |
Working Capital |
2,144.12 | 2,238.87 | 2,312.08 | 1,836.55 | |
Capital Expenditures |
(0.41) | (0.65) | (0.50) | (0.52) | |
Net Current Asset Value |
1,376.74 | 1,467.55 | 1,537.10 | 1,642.24 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.06 | 0.35 | 0.60 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
16.19 | 10.53 | 13.36 | 12.92 | |
Average Assets |
2,400.86 | 2,340.24 | 2,445.96 | 2,253.64 | |
Average Common Equity |
1,782.03 | 1,728.84 | 1,821.86 | 1,926.95 |
Columns are period end dates · fundamentals updated 6 Nov 2026